40 research outputs found

    MixInYeast: A Multicenter Study on Mixed Yeast Infections

    Get PDF
    Invasive candidiasis remains one of the most prevalent systemic mycoses, and several studies have documented the presence of mixed yeast (MY) infections. Here, we describe the epidemiology, clinical, and microbiological characteristics of MY infections causing invasive candidiasis in a multicenter prospective study. Thirty-four centers from 14 countries participated. Samples were collected in each center between April to September 2018, and they were sent to a reference center to confirm identification by sequencing methods and to perform antifungal susceptibility testing, according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST). A total of 6895 yeast cultures were identified and MY occurred in 150 cases (2.2%). Europe accounted for the highest number of centers, with an overall MY rate of 4.2% (118 out of 2840 yeast cultures). Of 122 MY cases, the most frequent combinations were Candida albicans/C. glabrata (42, 34.4%), C. albicans/C. parapsilosis (17, 14%), and C. glabrata/C. tropicalis (8, 6.5%). All Candida isolates were susceptible to amphotericin B, 6.4% were fluconazole-resistant, and two isolates (1.6%) were echinocandin-resistant. Accurate identification of the species involved in MY infections is essential to guide treatment decisions

    International Society of Human and Animal Mycology (ISHAM)-ITS reference DNA barcoding database - the quality controlled standard tool for routine identification of human and animal pathogenic fungi

    Get PDF
    Human and animal fungal pathogens are a growing threat worldwide leading to emerging infections and creating new risks for established ones. There is a growing need for a rapid and accurate identification of pathogens to enable early diagnosis and targeted antifungal therapy. Morphological and biochemical identification methods are time-consuming and require trained experts. Alternatively, molecular methods, such as DNA barcoding, a powerful and easy tool for rapid monophasic identification, offer a practical approach for species identification and less demanding in terms of taxonomical expertise. However, its wide-spread use is still limited by a lack of quality-controlled reference databases and the evolving recognition and definition of new fungal species/complexes. An international consortium of medical mycology laboratories was formed aiming to establish a quality controlled ITS database under the umbrella of the ISHAM working group on "DNA barcoding of human and animal pathogenic fungi." A new database, containing 2800 ITS sequences representing 421 fungal species, providing the medical community with a freely accessible tool at http://www.isham.org and http://its.mycologylab.org/ to rapidly and reliably identify most agents of mycoses, was established. The generated sequences included in the new database were used to evaluate the variation and overall utility of the ITS region for the identification of pathogenic fungi at intra-and interspecies level. The average intraspecies variation ranged from 0 to 2.25%. This highlighted selected pathogenic fungal species, such as the dermatophytes and emerging yeast, for which additional molecular methods/genetic markers are required for their reliable identification from clinical and veterinary specimens.This study was supported by an National Health and Medical Research Council of Australia (NH&MRC) grant [#APP1031952] to W Meyer, S Chen, V Robert, and D Ellis; CNPq [350338/2000-0] and FAPERJ [E-26/103.157/2011] grants to RM Zancope-Oliveira; CNPq [308011/2010-4] and FAPESP [2007/08575-1] Fundacao de Amparo Pesquisa do Estado de So Paulo (FAPESP) grants to AL Colombo; PEst-OE/BIA/UI4050/2014 from Fundacao para a Ciencia e Tecnologia (FCT) to C Pais; the Belgian Science Policy Office (Belspo) to BCCM/IHEM; the MEXBOL program of CONACyT-Mexico, [ref. number: 1228961 to ML Taylor and [122481] to C Toriello; the Institut Pasteur and Institut de Veil le Sanitaire to F Dromer and D Garcia-Hermoso; and the grants from the Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) and the Fundacao de Amparo a Pesquisa do Estado de Goias (FAPEG) to CM de Almeida Soares and JA Parente Rocha. I Arthur would like to thank G Cherian, A Higgins and the staff of the Molecular Diagnostics Laboratory, Division of Microbiology and Infectious Diseases, Path West, QEII Medial Centre. Dromer would like to thank for the technical help of the sequencing facility and specifically that of I, Diancourt, A-S Delannoy-Vieillard, J-M Thiberge (Genotyping of Pathogens and Public Health, Institut Pasteur). RM Zancope-Oliveira would like to thank the Genomic/DNA Sequencing Platform at Fundacao Oswaldo Cruz-PDTIS/FIOCRUZ [RPT01A], Brazil for the sequencing. B Robbertse and CL Schoch acknowledge support from the Intramural Research Program of the NIH, National Library of Medicine. T Sorrell's work is funded by the NH&MRC of Australia; she is a Sydney Medical School Foundation Fellow.info:eu-repo/semantics/publishedVersio

    Identification of medical fungi with MALDI-TOF MS : application of diagnosis to fungal diseases

    No full text
    L’avĂšnement de la spectromĂ©trie de masse de type MALDI-TOF a rĂ©volutionnĂ© la microbiologie en permettant l’identification prĂ©cise des bactĂ©ries et des levures en seulement quelques minutes. En 2010, la MALDI-TOF SM n’était pas applicable Ă  l’identification des champignons filamenteux. Un protocole d’identification gĂ©nĂ©rant des spectres interprĂ©tables de champignons filamenteux fut d’abord mis au point, suivi par le dĂ©veloppement d’une architecture de banque originale. Enfin une banque de rĂ©fĂ©rences solides, intĂ©grant des rĂ©fĂ©rences pour la majoritĂ© des espĂšces de moisissures impliquĂ©es en pathologie humaine, fut crĂ©Ă©e en collaboration avec le BCCM/IHEM. Les qualitĂ©s d’identification de cette banque ont Ă©tĂ© dĂ©montrĂ©es non seulement Ă  l’échelle localemais Ă©galement Ă  l’échelle nationale . Dans un second temps, nous sommes intĂ©ressĂ©s Ă  l’identification des levures. Nous avons dĂ©terminĂ© qu’une extraction complĂšte est le meilleur protocole d’identification des levures en utilisant la banque de rĂ©fĂ©rence Bruker ℱ. Afin d’amĂ©liorer le diagnostic clinique,nous avons testĂ© un protocole d’identification sur un sĂ©ries de 6192 levures isolĂ©es de prĂ©lĂšvements cliniques reçus au laboratoire pendant un an. Enfin nous avons pu dĂ©montrer en utilisant nos « systĂšmes » d’identification par MALDI-TOF MS la sous-estimation de la diversitĂ© des espĂšces de moisissures et de levures isolĂ©es des prĂ©lĂšvements cliniques, lorsqu’on ne disposait que de techniques conventionnelles d’identification. La mise Ă  disposition d’un tel outil ouvre de grandes perspectives dans le domaine de la mycologie, tant d’un point de vue Ă©pidĂ©miologique que clinique.During the last decade, MALDI-TOF MS has revolutionized microbiology by enabling the accurate identification of bacteria and yeast in only few minutes1. At the beginning of this work in 2010, MALDI-TOF MS was not yet optimized for mold identification. To meet this need, we established an identification protocol to generate interpretable mold spectra. The structure of the reference database was developed taking intoaccount the heterogeneity of molds in culture. Finally, a comprehensive reference database,including references for the majority of molds encountered in human pathology, was created in collaboration with the BCCM/IHEM. Identification performance of this database was tested and validated at both a local scale and an international scale . We also determined the best-adapted pre-treatment protocol to identify yeasts in a routine setting. The protocol was tested on a panel of 6192 yeast isolates recovered from clinical samples submitted to our laboratory over the course of one year. Using our fungal identification system, we were able to identify morphologically similar species and highlight the underestimation of fungal pathogen diversity. The development of our MALDI-TOF MS-based fungal identification system presents numerous opportunities in the field of mycological, from both an epidemiological and clinical point of view. In subsequent studies, defining the clinical meaning of emerging species identified via MALDI-TOF MS will profoundly modify our perspective of fungal diseases

    Repurposing of ribavirin as an adjunct therapy against invasive Candida strains: In vitro study

    No full text
    International audienc

    Saccharomyces cerevisiae osteomyelitis in an immunocompetent baker

    Get PDF
    Invasive infection caused by Saccharomyces cerevisiae is rare. We report the first case of osteomyelitis caused by S. cerevisiae (baker's yeast) in a post-traumatic patient. The clinical outcome was favorable after surgical debridement, prolonged antifungal treatment and hyperbaric oxygen therapy

    Performance of MALDI-TOF MS platforms for fungal identification

    No full text
    International audienceMatrix-assisted laser desorption/ionisation mass spectrometry (MALDI-TOF MS) is increasingly used by clinical microbiology laboratories to cope with the need for rapid, cost-effective and accurate identification of microorganisms. Several research teams have recently succeed in identifying moulds using MALDI-TOF MS, which was first adapted to bacteria, then to yeast identification. Since 2004, different commercial firms have released several ready-to-use MALDI-TOF MS platforms. This review describes the similarities and differences between the commercially available systems. In two parts, we first describe and compare the preprocessing and identification steps between the platforms and then compare the identification efficacy of yeast, moulds and dermatophytes species

    Malignant Aspergillus flavus Otitis Externa with Jugular Thrombosis

    No full text
    We report a case of malignant otitis externa with jugular vein thrombosis caused by Aspergillus flavus. Magnetic resonance imaging revealed an unusual ink smudge pattern deep in a cervical abscess. The pattern was consistent with mycetoma and may be important for diagnosing these life-threatening infections
    corecore